Acasunlimab

Phase 2Monoclonal antibody

Genmab

Acasunlimab is one of 80 biologic programs targeting Solid Tumor. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid TumorActive, not recruiting

Lung CancerActive, not recruiting

Solid TumorPreclinical

Active, not recruiting

Lung CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Fludara

Sanofi

Preclinical

1 2

DATROWAY

Daiichi Sankyo

Preclinical

1 3

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 4

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 5

Acasunlimab

Genmab

Phase 2

1 6

Navmi

SSummit Therapeutics

Preclinical

1 7

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 8

PD-1 Inhibitor

Johnson & Johnson

Preclinical

1 9

Tulmimetostat

Novartis

Preclinical

1 10

SAR445877

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Active, not recruiting

Lung Cancer

NCT05117242

Q3 2028

Phase 3Active, not recruiting

PD-L1-Positive, Locally Advanced (unresectable Stage IIIB/C) or Metastatic NSCLC

NCT06635824

Clinical

Trials by Indication[1]

Advanced Solid Malignancies1 trial

GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies

Completed· Genmab logo

Genmab·Phase 1·NCT04937153·18 enrolled

Endometrial Cancer1 trial

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

Withdrawn· Genmab logo

Genmab·Phase 2·NCT06046274

Lung Cancer1 trial

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

Active, not recruiting· Genmab logo

Genmab·Phase 2·NCT05117242·125 enrolled

PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC1 trial

A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)

Active, not recruiting· Genmab logo

Genmab·Phase 3·NCT06635824·191 enrolled

Solid Tumor1 trial

First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1046 in Subjects With Malignant Solid Tumors

Terminated· Genmab logo

Genmab·Preclinical·NCT03917381·429 enrolled

1 more indication

Cutaneous Melanoma1 trial

Efficacy and Safety Study of Acasunlimab as Monotherapy and in Combination With Pembrolizumab in Subjects With Relapsed/Refractory, Unresectable Locally Advanced or Metastatic Cutaneous Melanoma That Progressed On or After Treatment With a Checkpoint Inhibitor (ABBIL1TY MELANOMA-07)

Terminated· Genmab logo

Genmab·Phase 2·NCT06984328·1 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Acasunlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Acasunlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Acasunlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Genmab company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: Genmab

Acasunlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2028

Trials by Indication[1]

Advanced Solid Malignancies1 trial

Endometrial Cancer1 trial

Lung Cancer1 trial

PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC1 trial

Solid Tumor1 trial

Cutaneous Melanoma1 trial

References

Drug Info

Quick Facts

Related News